A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

Pembrolizumab (+) Berahyaluronidase alfaOngoingActive not recruitingPhase 2Open NCT06504394 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…